The LUNA-2 trial will pair immunotherapy with fecal microbiota transplantation (FMT) to boost treatment effectiveness in people with non-small cell lung cancer. If successful, it could provide new treatment options for those living with the disease, helping them live longer and with fewer side effects.
Two Canadian clinical trials have shown that fecal microbiota transplants (FMT) can improve the response to immunotherapy in patients with lung cancer and melanoma. FMT capsules were found to reduce toxic side effects of kidney cancer treatment, potentially leading to improved patient outcomes.
A new imaging solution, PSMA PET scanning, has been found to effectively detect the recurrence of prostate cancer compared to standard methods, leading to improved survival outcomes. The study also showed that patients who had their treatments modified based on results from the scan had a better overall survival rate.
A Phase II clinical trial is being conducted to treat renal cell carcinoma (kidney cancer) by inserting microscopic beads filled with radiation directly into blood vessels surrounding cancerous tumours. The goal is to improve patient outcomes through a new treatment option.
A new type of dialysis filter called Elisio HX is being tested in a clinical trial to determine if it improves survival rates and reduces hospitalizations for patients with kidney failure. The five-year multicentre randomized trial will include up to 4,800 patients across Canada.
A clinical trial found that high tibial osteotomy (HTO) reduces knee joint damage and improves pain and function in patients with knee osteoarthritis and bowed legs. HTO alters the way people walk, lessening further joint damage, reducing pain, and improving quality of life.
A new ventilation mode called proportional assist ventilation (PAV+) has been found to improve outcomes for critically ill patients on ventilators. PAV+ reduces the need for sedation and delirium in ICU patients, leading to faster recovery times.
A clinical trial led by London Health Sciences Centre Research Institute has improved the detection of hidden blood clots responsible for strokes by extending imaging to include the heart. This approach has increased detection rates by 500% and can help determine an effective treatment plan.
A study published in PLOS One found that mouth taping carries serious health risks, particularly among individuals with sleep-disordered breathing and obstructive sleep apnea. The trend, popularized by social media influencers, can worsen existing respiratory issues and increase the risk of suffocation.
A new study by researchers at London Health Sciences Centre Research Institute found an association between long-term exposure to air pollution and new cases of epilepsy in adults in Ontario. Higher exposure to fine particulate matter and ozone increased the likelihood of developing epilepsy.
A groundbreaking Phase I safety trial aims to enhance patients' immune response and boost chemotherapy effectiveness. Researchers hope that shifting the gut microbiome will lead to a better response to conventional therapies among patients with advanced pancreatic cancer.
A new Phase I clinical trial from London Health Sciences Centre Research Institute found high-precision radiation therapy to be safe in treating patients with polymetastatic disease. The study, known as ARREST, used stereotactic ablative radiotherapy (SABR) to treat cancer that has spread to more than 10 spots in the body.
The London Health Sciences Centre was the first and only hospital in Canada to implant a new extravascular implantable cardioverter defibrillator (ICD) during clinical trials. The device has been shown to provide long-term safety, efficacy, and performance, offering better comfort and care for patients.
LHSCRI is the first in Canada to treat a patient with neuroendocrine tumours using actinium-225 DOTATATE, a type of theranostics therapy. The treatment aims to precisely locate and eradicate cancer cells, potentially extending patients' quality of life and life expectancy.